GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioventix PLC (LSE:BVXP) » Definitions » Capex-to-Operating-Cash-Flow

Bioventix (LSE:BVXP) Capex-to-Operating-Cash-Flow : 0.00 (As of Jun. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Bioventix Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Bioventix's Capital Expenditure for the six months ended in Jun. 2024 was £-0.01 Mil. Its Cash Flow from Operations for the six months ended in Jun. 2024 was £3.94 Mil.

Hence, Bioventix's Capex-to-Operating-Cash-Flow for the six months ended in Jun. 2024 was 0.00.


Bioventix Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Bioventix's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioventix Capex-to-Operating-Cash-Flow Chart

Bioventix Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.04 0.04 - - -

Bioventix Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Bioventix's Capex-to-Operating-Cash-Flow

For the Biotechnology subindustry, Bioventix's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bioventix's Capex-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bioventix's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Bioventix's Capex-to-Operating-Cash-Flow falls into.



Bioventix Capex-to-Operating-Cash-Flow Calculation

Bioventix's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Jun. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-0.016) / 8.344
=0.00

Bioventix's Capex-to-Operating-Cash-Flow for the quarter that ended in Jun. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-0.011) / 3.944
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bioventix  (LSE:BVXP) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Bioventix Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Bioventix's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Bioventix Business Description

Industry
Traded in Other Exchanges
Address
27–28 Eastcastle Street, London, GBR, W1W 8DH
Bioventix PLC is a biotechnology company based in the United Kingdom. It specializes in the creation and supply of high-affinity sheep monoclonal antibodies and clinical diagnostics and drug abuse testing. The company's portfolio of products includes drugs that are applicable in the areas of cardiology, fertility, infectious diseases, Thyroid, and vitamin D disorder among others. It earns maximum revenue from European country.

Bioventix Headlines

No Headlines